



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

May 25, 2022

Corporate Relationship Department
M/s. BSE Ltd.
Dalal Sreet, Fort
Mumbai 400 001

Manager – Listing
M/s. National Stock Exchange of India Ltd
“Exchange Plaza”, Bandra – Kurla Complex
Bandra (E) Mumbai 400 051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir

Please find enclose herewith the Disclosure under Regulation 30 of SEBI (LODR) Regulations 2015 for your information.

Thanking you

Yours faithfully
For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Ref: PR/ 2 /2022-23

LEGAL UPDATE- GLATIRAMER ACETATE

Hyderabad, India, May 25th, 2022

NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) would like to update that Johnson & Johnson's and Momenta Pharmaceuticals has filed a lawsuit against NATCO and its marketing partner Mylan Pharmaceuticals Inc. (Mylan) & others alleging infringement of two old Patents associated with 20mg/ml and 40mg/ml Glatiramer Acetate Injection.

This lawsuit has been filed in the Pennsylvania Federal Court. NATCO and its marketing partner, Mylan believe this is a meritless suit for a product that has been in the market for more than 5 years. Mylan and NATCO will strongly defend against this suit.

For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer